CHMP Opinion

Calgary, Alberta — November 18, 2025 — Resverlogix Corp. (TSX: RVX), a late-stage biotechnology firm specializing in epigenetic therapies,...

RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...

Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...